<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042687</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0927</org_study_id>
    <nct_id>NCT05042687</nct_id>
  </id_info>
  <brief_title>Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer</brief_title>
  <official_title>Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in&#xD;
      women who are at high risk for developing breast cancer.&#xD;
&#xD;
      To assess the relationship of tumor size, histologic subtype and location of lesion and how&#xD;
      it affects lesion conspicuity and sensitivity in MBI detected cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      -To compare the diagnostic performance of Molecular Breast Imaging (MBI) to breast Magnetic&#xD;
      Resonance Imaging (MRI) in women who are at high risk of developing breast cancer.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative&#xD;
           predictive value (NPV) of MBI compared to breast MRI in women who are at high risk of&#xD;
           developing breast cancer.&#xD;
&#xD;
        -  To assess patient preference for the two examinations by conducting a post examination&#xD;
           survey and follow up questionnaire (see addendum).&#xD;
&#xD;
        -  To assess the relationship of tumor size, histologic subtype and location of lesion with&#xD;
           lesion conspicuity (mild, moderate, marked uptake compared to background activity)&#xD;
           according to MBI lexicon [1].&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 30, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To establish the diagnostic performance of Molecular Breast Imaging (MBI) to breast Magnetic Resonance Imaging (MRI) in women who are at high risk of developing breast cancer</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tc99m sestamibi</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBI uses an injection of a small amount of radioactive material called technetium99m (Tc99m) sestamibi</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tc99m sestamibi</intervention_name>
    <description>Given by IV</description>
    <arm_group_label>Tc99m sestamibi</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subjects to be studied will include female patients ages 18 and older of any race,&#xD;
             identified as carrying an elevated risk for breast cancer referred to MDACC.&#xD;
&#xD;
          -  High risk may be defined as having a calculated lifetime risk &gt;20%, histopathology of&#xD;
             lobular neoplasia or atypical ductal hyperplasia, atypia NOS or a genetic mutation&#xD;
             known to predispose the patient to breast cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are pregnant will be excluded as MBI exam involves injection of&#xD;
             radioactive tracer&#xD;
&#xD;
          -  contrast enhanced MRI involves gadolinium injection, both of which are contraindicated&#xD;
             during pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah L Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah L Chung</last_name>
    <phone>(713) 745-4555</phone>
    <email>hlchung@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Hannah L Chung</last_name>
      <phone>713-745-4555</phone>
      <email>hlchung@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Hannah L Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

